Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices for their recently approved meningitis B vaccines. There's just one problem: It doesn't cover nearly as large a population as the pharma giants would like.
Bayer said earlier this week that it would be counting on eye blockbuster Eylea to provide some serious sales growth in 2015, and now, it has a new indication the company hopes can help it get there.
Paris-based clinical biotech ABIVAX said it has recruited its first patient for an Asia Pacific-based pivotal Phase IIb-III clinical trial of a potential vaccine therapy of chronic hepatitis B.
Japan's health ministry on Friday told the local unit of Swiss-based Novartis to suspend most sales operations for just over two weeks.
It turns out the GlaxoSmithKline whistleblowers who blew the top off the China corruption scandal had hundreds of copycats later on.
China's Tianyin Pharmaceutical may be in danger of being de-listed from the New York Stock Exchange for failing to file its latest quarterly report on time.
India's Central Drugs Standard Control Organization has recommended new guidelines for Phase III trial drug trial waivers.
Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like.
Boston Scientific touted its new cleared endoscopic SpyGlass DS Direct Visualization System enabling direct visualization of the biliary tree and pancreatic ducts. With the FDA's 510(k) clearance now in hand, the device can hit the market.
Continuous glucose monitor company DexCom turned a profit for the first time during the fourth quarter of last year. It also said it completed its FDA submission for its first direct-access smartphone CGM, the G5, which transmits data directly to a smartphone and from the phone to a secure system.